July saw predictions of device “gold rushes”, long-term data, and new partnerships, with Ziv Haskal (University of Virginia School of Medicine, Charlottesville, USA) and Timothy Clark (Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA) discussing the future of thrombectomies following the ATTRACT study, the publication of new data from both the AVeNEW trial and IN.PACT AV study, and a new US-based partnership between Alliance for Paired Kidney Donation (APKD) and MedSleuth.
At the recent Endo Vascular Access (EVA) meeting (14–15 June, Patras, Greece), Renal Interventions editorial board member Ziv Haskal (University of Virginia School of Medicine, Charlottesville, USA) spoke to Timothy Clark (Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA) about what they referred to as the “gold rush” of thrombectomy devices for large-calibre blood vessels.
Xeltis has announced today the appointment of Shawn Gage as its new vice president of US clinical affairs. The company stated that his appointment comes at “a pivotal time”, at which it is advancing the initiation of its US-based pivotal trial for aXess, its restorative vascular access conduit.
Surgeons at Northwestern Medicine (Chicago, USA) have, for the first time, performed a kidney transplant procedure where the patient was awake during the entire surgery and was discharged the next day. The patient, 28-year-old John Nicholas, felt no pain during the procedure and was home less than 24-hours after surgery.
“Study design is critically important when interpreting outcomes,” said Bart Dolmatch (Mountain View Hospital, Mountain View, USA) in his evaluation of the “disconnect” between target lesion primary patency (TLPP) and access circuit primary patency (ACPP) analysing AVeNEW study data at this year’s Endo Vascular Access (EVA) meeting (14–15 June, Patras, Greece).
VentureMed Group have announced this week that it has completed enrolment of the FLEX First arteriovenous (AV) Registry, which was designed to treat subjects with AV fistulas (AVF)/AV grafts (AVG) stenosis to demonstrate the FLEX Vessel Prep System combined with balloon angioplasty will improve the rate of target lesion primary patency, as compared with comparable published rates of balloon angioplasty alone.
The first patients in the USA have been treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS), a real-world study gathering data on the long-term safety and effectiveness of ultrasound renal denervation.
Matteo Tozzi (Varese, Italy) and Kate Steiner (Stevenage, UK) sat down with Renal Interventions at this year’s Charing Cross (CX) International Symposium (23–25 April, London, UK) to provide their thoughts on the latest findings from the IN.PACT AV Access randomised controlled trial (RCT) evaluating the IN.PACT AV drug-coated balloon (DCB; Medtronic) in dialysis patients with dysfunctional arteriovenous fistulas (AVFs).
King Faisal Specialist Hospital and Research Centre (KFSHRC: Riyadh, Saudi Arabia) has recently announced that it has successfully performed 5,000 kidney transplants since the inception of its transplant programme in 1981, placing it among a select group of leading global health centres that have achieved this milestone.
The Alliance for Paired Kidney Donation (APKD) and transplant software company MedSleuth have announced a US partnership launched to increase access to lifesaving kidney transplants. The organisations have consolidated their two paired kidney donation software platforms into one programme, named Kidney Matchgrid, which they state will significantly expand the pool for matching living kidney donors with transplant candidates nationwide.
- Renalys Pharma closes ¥6 billion Series A financing to advance kidney disease treatments across Asia
Renalys Pharma has recently announced completion of a ¥6 billion Series A financing. The financing was led by Catalys Pacific and SR One, along with additional investors, including JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank company Limited, Japan Co-Invest IV Limited Partnership, and NVCC NO.9 Investment Limited Partnership.
